S&P 500   3,169.56 (+0.03%)
DOW   28,146.97 (+0.05%)
QQQ   207.29 (+0.38%)
AAPL   275.10 (+1.34%)
FB   193.82 (-1.49%)
MSFT   154.51 (+0.82%)
GOOGL   1,349.37 (+0.07%)
AMZN   1,762.77 (+0.14%)
NVDA   224.92 (+0.38%)
BABA   205.09 (+0.29%)
GE   11.37 (-0.61%)
T   38.25 (-0.26%)
AMD   41.33 (-2.98%)
ACB   2.63 (+0.77%)
NFLX   298.41 (-0.01%)
BAC   34.49 (-0.58%)
GILD   65.84 (-2.65%)
DIS   146.74 (-0.69%)
S&P 500   3,169.56 (+0.03%)
DOW   28,146.97 (+0.05%)
QQQ   207.29 (+0.38%)
AAPL   275.10 (+1.34%)
FB   193.82 (-1.49%)
MSFT   154.51 (+0.82%)
GOOGL   1,349.37 (+0.07%)
AMZN   1,762.77 (+0.14%)
NVDA   224.92 (+0.38%)
BABA   205.09 (+0.29%)
GE   11.37 (-0.61%)
T   38.25 (-0.26%)
AMD   41.33 (-2.98%)
ACB   2.63 (+0.77%)
NFLX   298.41 (-0.01%)
BAC   34.49 (-0.58%)
GILD   65.84 (-2.65%)
DIS   146.74 (-0.69%)
S&P 500   3,169.56 (+0.03%)
DOW   28,146.97 (+0.05%)
QQQ   207.29 (+0.38%)
AAPL   275.10 (+1.34%)
FB   193.82 (-1.49%)
MSFT   154.51 (+0.82%)
GOOGL   1,349.37 (+0.07%)
AMZN   1,762.77 (+0.14%)
NVDA   224.92 (+0.38%)
BABA   205.09 (+0.29%)
GE   11.37 (-0.61%)
T   38.25 (-0.26%)
AMD   41.33 (-2.98%)
ACB   2.63 (+0.77%)
NFLX   298.41 (-0.01%)
BAC   34.49 (-0.58%)
GILD   65.84 (-2.65%)
DIS   146.74 (-0.69%)
S&P 500   3,169.56 (+0.03%)
DOW   28,146.97 (+0.05%)
QQQ   207.29 (+0.38%)
AAPL   275.10 (+1.34%)
FB   193.82 (-1.49%)
MSFT   154.51 (+0.82%)
GOOGL   1,349.37 (+0.07%)
AMZN   1,762.77 (+0.14%)
NVDA   224.92 (+0.38%)
BABA   205.09 (+0.29%)
GE   11.37 (-0.61%)
T   38.25 (-0.26%)
AMD   41.33 (-2.98%)
ACB   2.63 (+0.77%)
NFLX   298.41 (-0.01%)
BAC   34.49 (-0.58%)
GILD   65.84 (-2.65%)
DIS   146.74 (-0.69%)
Log in

NASDAQ:EARS - Auris Medical Stock Price, Forecast & News

$1.38
-0.02 (-1.43 %)
(As of 12/13/2019 03:48 PM ET)
Today's Range
$1.36
Now: $1.38
$1.42
50-Day Range
$1.31
MA: $1.52
$1.80
52-Week Range
$1.30
Now: $1.38
$10.90
Volume26,816 shs
Average Volume111,186 shs
Market Capitalization$2.58 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.55
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EARS
CUSIPN/A
Phone41-41-729-7194

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.99 per share

Profitability

Miscellaneous

Employees9
Market Cap$2.58 million
Next Earnings Date12/19/2019 (Estimated)
OptionableNot Optionable

Receive EARS News and Ratings via Email

Sign-up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.


Auris Medical (NASDAQ:EARS) Frequently Asked Questions

What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

When did Auris Medical's stock split? How did Auris Medical's stock split work?

Auris Medical shares reverse split on the morning of Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.

How were Auris Medical's earnings last quarter?

Auris Medical Holding Ltd (NASDAQ:EARS) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) EPS for the quarter, missing the consensus estimate of ($2.80) by $1.60. View Auris Medical's Earnings History.

When is Auris Medical's next earnings date?

Auris Medical is scheduled to release their next quarterly earnings announcement on Thursday, December 19th 2019. View Earnings Estimates for Auris Medical.

What price target have analysts set for EARS?

1 brokerages have issued twelve-month price objectives for Auris Medical's shares. Their forecasts range from $100.00 to $100.00. On average, they expect Auris Medical's stock price to reach $100.00 in the next twelve months. This suggests a possible upside of 7,146.4% from the stock's current price. View Analyst Price Targets for Auris Medical.

What is the consensus analysts' recommendation for Auris Medical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.

Has Auris Medical been receiving favorable news coverage?

Media stories about EARS stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Auris Medical earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Auris Medical.

Are investors shorting Auris Medical?

Auris Medical saw a decline in short interest during the month of November. As of November 29th, there was short interest totalling 5,700 shares, a decline of 19.7% from the November 14th total of 7,100 shares. Based on an average trading volume of 151,900 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.4% of the shares of the stock are short sold. View Auris Medical's Current Options Chain.

Who are some of Auris Medical's key competitors?

What other stocks do shareholders of Auris Medical own?

Who are Auris Medical's key executives?

Auris Medical's management team includes the folowing people:
  • Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)
  • Mr. Hernan Levett C.P.A., CPA, Chief Financial Officer (Age 43)
  • Colleen A. DeVries, SVP of Cogency Global Inc.

Who are Auris Medical's major shareholders?

Auris Medical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (8.96%).

Which major investors are buying Auris Medical stock?

EARS stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC.

How do I buy shares of Auris Medical?

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Auris Medical's stock price today?

One share of EARS stock can currently be purchased for approximately $1.38.

How big of a company is Auris Medical?

Auris Medical has a market capitalization of $2.58 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($14.80) on an earnings per share basis. Auris Medical employs 9 workers across the globe.View Additional Information About Auris Medical.

What is Auris Medical's official website?

The official website for Auris Medical is http://www.aurismedical.com/.

How can I contact Auris Medical?

Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]


MarketBeat Community Rating for Auris Medical (NASDAQ EARS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  356 (Vote Outperform)
Underperform Votes:  343 (Vote Underperform)
Total Votes:  699
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: Blue-Chip Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel